Levemir Related Published Studies
Well-designed clinical trials related to Levemir (Insulin Detemir Subcutaneous)
Insulin detemir in a twice daily insulin regimen versus a three times daily insulin regimen in the treatment of type 1 diabetes in children: A pilot randomized controlled trial. [2011.11.08]
Comparison of 2 intensification regimens with rapid-acting insulin aspart in type 2 diabetes mellitus inadequately controlled by once-daily insulin detemir and oral antidiabetes drugs: the step-wise randomized study. [2011.09.01]
Basal insulin analogues in diabetic pregnancy: a literature review and baseline results of a randomised, controlled trial in type 1 diabetes. [2011.09]
Optimized glycaemic control achieved with add-on basal insulin therapy improves indexes of endothelial damage and regeneration in type 2 diabetic patients with macroangiopathy: a randomized crossover trial comparing detemir versus glargine. [2011.08]
Insulin detemir reduces weight gain as a result of reduced food intake in patients with type 1 diabetes. [2011.07]
Pharmacokinetics and pharmacodynamics of therapeutic doses of basal insulins NPH, glargine, and detemir after 1 week of daily administration at bedtime in type 2 diabetic subjects: a randomized cross-over study. [2011.06]
Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial. [2011.03]
Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. [2011.02]
Do different body colors and labels of insulin pens enhance a patient's ability to correctly identify pens for injecting long-acting versus short-acting insulins? [2011.01.01]
[Costs of diabetes care and treatment satisfaction in type 2 diabetes patients treated with a basal-bolus (ICT) insulin regimen in outpatient care: results of the LIVE-COM study]. [2010.11]
Evaluation of the long-term cost-effectiveness of insulin detemir compared with neutral protamine hagedorn insulin in patients with type 1 diabetes using a basal-bolus regimen in Sweden. [2010.08.05]
Pharmacodynamics of insulin detemir and insulin glargine assessed by an isoglycemic clamp method in healthy cats. [2010.07]
Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans. [2010.07]
A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. [2010.06]
Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes. [2010.05]
[Optimal timing of insulin detemir injection in patients with type 1 diabetes and poor metabolic control] [2010.04]
A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes. [2010.02]
Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany. [2010.02]
No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring. [2010.01.01]
Comparing insulins detemir and glargine in type 2 diabetes: more similarities than differences. Commentary. [2010.01]
Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes. [2009.11]
Three-year efficacy of complex insulin regimens in type 2 diabetes. [2009.10.29]
Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial. [2009.10]
Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins. [2009.10]
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. [2009.08]
Study rationale and design of the CIMT trial: the Copenhagen Insulin and Metformin Therapy trial. [2009.04]
Comparison of intuitiveness, ease of use, and preference in two insulin pens. [2009.03.01]
Comparison of Inpatient Insulin Regimens with Detemir plus Aspart Versus Neutral Protamine Hagedorn plus Regular in Medical Patients with Type 2 Diabetes. [2009.02]
Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. [2009.01]
Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. [2008.12]
Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. [2008.08.27]
Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. [2008.08]
Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. [2008.08]
Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. [2008.07.17]
Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. [2008.04]
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. [2008.03]
Different brain responses to hypoglycemia induced by equipotent doses of the long-acting insulin analog detemir and human regular insulin in humans. [2008.03]
Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. [2008.01]
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. [2007.10.25]
Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study. [2007.10]
Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. [2007.06]
Prandial premixed insulin analogue regimens versus Basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. [2007.06]
Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. [2007.05]
Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. [2007.01]
Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. [2007]
Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. [2007]
Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. [2006.09]
Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. [2006.07]
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. [2006.06]
Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. [2005.07]
A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. [2005.05]
Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. [2005.01]
Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. [2005.01]
Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. [2004.11]
The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. [2004.10]
Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. [2004.06]
Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. [2004.05]
Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. [2004.05]
Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. [2004.04]
Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. [2003.11]
Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. [2003.03]
Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. [2001.02]
Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. [2000]
Well-designed clinical trials possibly related to Levemir (Insulin Detemir Subcutaneous)
Challenges of maintaining research protocol fidelity in a clinical care setting: a qualitative study of the experiences and views of patients and staff participating in a randomized controlled trial. [2011.05.04]
Other research related to Levemir (Insulin Detemir Subcutaneous)
Effects of insulin detemir and NPH insulin on renal handling of sodium, fluid retention and weight in type 2 diabetic patients. [2012.01]
Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir &
bolus aspart in patients with poorly controlled type 2 diabetes mellitus - a
pilot study. [2012]
The alteration of aspart insulin pharmacodynamics when mixed with detemir
insulin. [2012]
Intensifying insulin therapy with insulin analog premixes: transitioning from
basal insulin in type 2 diabetes. [2012]
Preference for a new prefilled insulin pen compared with the original pen. [2011.12]
Non-inferiority of insulin glargine versus insulin detemir on blood glucose variability in type 1 diabetes patients: a multicenter, randomized, crossover study. [2011.12]
Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes. [2011.12]
Intensifying insulin therapy in type 2 diabetes mellitus: dosing options for insulin analogue premixes. [2011.11]
Experimental testing of skin reactions to insulin detemir in diabetes patients naive to insulin detemir. [2011.11]
Predictive characteristics of patients achieving glycaemic control with insulin after sulfonylurea failure. [2011.10]
Insulin detemir versus insulin glargine for type 2 diabetes mellitus. [2011.07.06]
Longacting insulin analogue detemir compared with NPH insulin in type 1 diabetes: a systematic review and metaanalysis. [2011.07]
Basal insulin analogues--a review of recent data on efficacy and safety. [2011.04]
Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring. [2011]
Long-acting insulin analogue detemir compared with NPH insulin in type 1
diabetes: a systematic review and meta-analysis. [2011]
Differences in insulin treatment satisfaction following randomized addition of
biphasic, prandial or basal insulin to oral therapy in type 2 diabetes. [2011]
Insulin detemir versus insulin glargine for type 2 diabetes mellitus. [2011]
Insulin detemir reduces weight gain as a result of reduced food intake in
patients with type 1 diabetes. [2011]
Comparison of 2 intensification regimens with rapid-acting insulin aspart in type
2 diabetes mellitus inadequately controlled by once-daily insulin detemir and
oral antidiabetes drugs: the step-wise randomized study. [2011]
Comparison of 3 algorithms for Basal insulin in transitioning from intravenous to
subcutaneous insulin in stable patients after cardiothoracic surgery. [2011]
Treatment with insulin detemir or NPH insulin in children aged 2-5 yr with type 1
diabetes mellitus. [2011]
Optimized glycaemic control achieved with add-on basal insulin therapy improves
indexes of endothelial damage and regeneration in type 2 diabetic patients with
macroangiopathy: a randomized crossover trial comparing detemir versus glargine. [2011]
Do different body colors and labels of insulin pens enhance a patient's ability
to correctly identify pens for injecting long-acting versus short-acting
insulins? [2011]
Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany. [2010.08.05]
Mixing insulin aspart with detemir does not affect glucose excursion in children with type 1 diabetes. [2010.08]
Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials. [2010.07]
An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog. [2010.06.01]
Are analogue insulins superior to human insulin in clinical practice? [2010.06]
The A1chieve study: a 60 000-person, global, prospective, observational study of basal, meal-time, and biphasic insulin analogs in daily clinical practice. [2010.05]
Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes. [2010.04]
Therapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps. [2010]
Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime
with mealtime insulin aspart in type 2 diabetes in Germany. [2010]
A randomized, treat-to-target trial comparing insulin lispro protamine suspension
and insulin detemir in insulin-naive patients with Type 2 diabetes. [2010]
Mixing insulin aspart with detemir does not affect glucose excursion in children
with type 1 diabetes. [2010]
A 24-week, randomized, treat-to-target trial comparing initiation of insulin
glargine once-daily with insulin detemir twice-daily in patients with type 2
diabetes inadequately controlled on oral glucose-lowering drugs. [2010]
No higher dose requirements with insulin detemir than glargine in type 2
diabetes: a crossover, double-blind, and randomized study using continuous
glucose monitoring. [2010]
Comparison of one-year costs of type 2 diabetes treatment with insulin glargine
or insulin detemir in a basal supported oral therapy (BOT) in Germany. [2010]
|
